However, it was apparent from Figure 3B that the expression percentages of classical MG and BMDM markers (P2RY12 and TMEM119 for MG, and ITGA4 and SELL for BMDM) from the 10x platform were significantly lower when compared with those from the Smart-Seq2 technique (4, 9, 23). This evidence concerns the gene SELL and myasthenia gravis.